InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, has wrapped up enrollment for its previously announced phase 2 clinical trial, which is called INM-755-201-EB and designed to evaluate the use of its proprietary investigational drug INM-755 cannabinol (“CBN”); the cream is being studied for the treatment of epidermolysis bullosa (“EB”), a rare genetic skin disease. According to the announcement, this marks the first time a phase 2 trial has studied a CBN formulation as a treatment option for any disease. The study enrolled a total of 19 participants, with all four EB subtypes — EB Simplex, Dystrophic EB, Junctional EB and Kindler Syndrome — being represented. The trial will be studying the safety and preliminary efficacy of INM-755 cannabinol cream in treating itching, pain and wound healing in patients with epidermolysis bullosa. The company anticipates releasing results from INM-755-201-EB in early calendar Q3 2023. “Enrollment completion of this phase 2 clinical trial of a cannabinol formulation represents an important milestone for InMed and the scientific community studying rare cannabinoids,” said InMed Pharmaceuticals president and CEO Eric A. Adams in the press release. “As a class of compounds, we believe cannabinoids hold tremendous therapeutic potential for their innate interaction with the body; however, to date there have been limited evidence-based studies investigating their effects. Taking a rare cannabinoid formulation through several phase 1 and phase 2 clinical trials has been a major undertaking. We look forward to the data read-out in the summer, so we can evaluate our strategic options and next steps.”
To view the full press release, visit https://ibn.fm/upuIs
About InMed Pharmaceuticals Inc.
InMed Pharmaceuticals is a global leader in the research, development and manufacturing of rare cannabinoids, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs. The company also has significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors. For more information, please visit www.InMedPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork